Furthermore, it is conceivable that the dysregulation of immunological mediators implicated in COVID-19, including IL-6, sIL-6R, and sgp130, may contribute to varied prognoses and responses to pharmacological interventions such as tocilizumab and steroids. The gene discussed is IL6R; the disease is COVID-19.